Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Vectura
January 17, 2022
Groups slam Philip Morris, but the Vectura deal has precedent
May 26, 2021
Vectura marks a sorry outcome for UK biotech
April 21, 2021
Coughing and sputtering, Hikma’s Advair generic comes back to life
January 06, 2021
US FDA approval tracker: December
November 30, 2020
Kinaset up for a tough ride with inhaled Jak focus
January 29, 2020
Novartis gives up trying to copy Advair
October 01, 2019
New clinical data request hits Astra’s lung triplet
July 17, 2019
Vectura moves to appease long-term shareholders
January 31, 2019
Mylan makes for a piece of the shrinking Advair pie
November 26, 2018
Vectura’s VR475 runs out of puff
September 05, 2018
Pojasek departure takes Immunocore’s C-suite bloodletting to six
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
April 20, 2022
Genetic Medicine: The Next Generation
March 18, 2022
PD(L)anner - March 2022
Editor's Picks
May 05, 2022
Bristol needs to get fresh
May 04, 2022
The next generation of diabetes technology
April 25, 2022
Nkarta: at least as good as Fate, at a tenth of the price
April 26, 2022
How Gal appointment could influence strategy at Novartis
May 01, 2020
US FDA approval tracker: April
